3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
18
pembrolizumab
16
Cisplatin
16
Nivolumab
15
atezolizumab
11
durvalumab
9
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cystectomy
8
Carboplatin
7
Ipilimumab
6
Fluorouracil
6
avelumab
5
Mitomycin
5
sacituzumab govitecan
4
erdafitinib
4
enfortumab vedotin
4
Surgical Procedures, Operative
4
Immunoglobulin G
4
Disulfides
4
Biopsy
4
tremelimumab
3
cabozantinib
3
Transurethral Resection of Bladder
3
Surveys and Questionnaires
3
Radiation
3
Platinum
3
Paclitaxel
3
Leucovorin
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Urinary Bladder Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled